Ciglitazone

C. Day, C. Bailey

Research output: Chapter in Book/Report/Conference proceedingEntry for encyclopedia/dictionary

Abstract

Ciglitazone was the first antidiabetic thiazolidinedione to be described in detail (Sohda et al., 1982). The thiazolidinediones (TZDs), also termed “glitazones”, activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Thiazolidinediones currently in clinical use for the treatment of type 2 diabetes are rosiglitazone (withdrawn in Europe in 2010) and pioglitazone. Another TZD, troglitazone, was withdrawn due to hepatotoxicity. Ciglitazone was not introduced into clinical use.
Original languageEnglish
Title of host publicationReference module in biomedical sciences
PublisherElsevier
ISBN (Print)978-0-12-801238-3
DOIs
Publication statusPublished - 2016

Fingerprint

Thiazolidinediones
rosiglitazone
pioglitazone
troglitazone
PPAR gamma
Hypoglycemic Agents
Type 2 Diabetes Mellitus
ciglitazone

Cite this

Day, C., & Bailey, C. (2016). Ciglitazone. In Reference module in biomedical sciences Elsevier. https://doi.org/10.1016/B978-0-12-801238-3.97236-2
Day, C. ; Bailey, C. / Ciglitazone. Reference module in biomedical sciences. Elsevier, 2016.
@inbook{5833469ea8b34fd7b1a6ef6360257b82,
title = "Ciglitazone",
abstract = "Ciglitazone was the first antidiabetic thiazolidinedione to be described in detail (Sohda et al., 1982). The thiazolidinediones (TZDs), also termed “glitazones”, activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Thiazolidinediones currently in clinical use for the treatment of type 2 diabetes are rosiglitazone (withdrawn in Europe in 2010) and pioglitazone. Another TZD, troglitazone, was withdrawn due to hepatotoxicity. Ciglitazone was not introduced into clinical use.",
author = "C. Day and C. Bailey",
year = "2016",
doi = "10.1016/B978-0-12-801238-3.97236-2",
language = "English",
isbn = "978-0-12-801238-3",
booktitle = "Reference module in biomedical sciences",
publisher = "Elsevier",
address = "Netherlands",

}

Day, C & Bailey, C 2016, Ciglitazone. in Reference module in biomedical sciences. Elsevier. https://doi.org/10.1016/B978-0-12-801238-3.97236-2

Ciglitazone. / Day, C.; Bailey, C.

Reference module in biomedical sciences. Elsevier, 2016.

Research output: Chapter in Book/Report/Conference proceedingEntry for encyclopedia/dictionary

TY - CHAP

T1 - Ciglitazone

AU - Day, C.

AU - Bailey, C.

PY - 2016

Y1 - 2016

N2 - Ciglitazone was the first antidiabetic thiazolidinedione to be described in detail (Sohda et al., 1982). The thiazolidinediones (TZDs), also termed “glitazones”, activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Thiazolidinediones currently in clinical use for the treatment of type 2 diabetes are rosiglitazone (withdrawn in Europe in 2010) and pioglitazone. Another TZD, troglitazone, was withdrawn due to hepatotoxicity. Ciglitazone was not introduced into clinical use.

AB - Ciglitazone was the first antidiabetic thiazolidinedione to be described in detail (Sohda et al., 1982). The thiazolidinediones (TZDs), also termed “glitazones”, activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Thiazolidinediones currently in clinical use for the treatment of type 2 diabetes are rosiglitazone (withdrawn in Europe in 2010) and pioglitazone. Another TZD, troglitazone, was withdrawn due to hepatotoxicity. Ciglitazone was not introduced into clinical use.

U2 - 10.1016/B978-0-12-801238-3.97236-2

DO - 10.1016/B978-0-12-801238-3.97236-2

M3 - Entry for encyclopedia/dictionary

SN - 978-0-12-801238-3

BT - Reference module in biomedical sciences

PB - Elsevier

ER -

Day C, Bailey C. Ciglitazone. In Reference module in biomedical sciences. Elsevier. 2016 https://doi.org/10.1016/B978-0-12-801238-3.97236-2